Anne V. Gonzalez

Anne V. Gonzalez

Auto-generated profile, based on publicly available information

Anne V. Gonzalez

McGill University Health Centre

Research Focus & Metrics

Academic Career Length

17Years (2010-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
15 March 2024 in American Journal of Respiratory and Critical Care Medicine
Verified
Journal Article
Open access
AGAnne V. Gonzalez
Anne V. Gonzalez
GSGerard A. Silvestri
Gerard A. Silvestri
DKDaniel Korevaar
Daniel Korevaar
YGYaron B. Gesthalter
Yaron B. Gesthalter
NANisha D. Almeida
Nisha D. Almeida
LYLonny B. Yarmus
Lonny B. Yarmus
Background: Advanced diagnostic bronchoscopy targeting the lung periphery has developed at an accelerated pace over the last two decades, whereas evidence to support introduction of innovative technologies has been variable and deficient. A major gap relates to variable reporting of diagnostic yield, in addition to limited comparative studies. Objectives: To develop a research framework to standardize the evaluation of advanced diagnostic bronchoscopy techniques for peripheral lung lesions. Specifically, we aimed for consensus on a robust definition of diagnostic yield, and we propose potential study designs at various stages of technology development. Methods: Panel members were selected for their diverse expertise. Workgroup meetings were conducted in virtual or hybrid format. The cochairs subsequently developed summary statements, with voting proceeding according to a modified Delphi process. The statement was cosponsored by the American Thoracic Society and the American College of Chest Physicians. Results: Consensus was reached on 15 statements on the definition of diagnostic outcomes and study designs. A strict definition of diagnostic yield should be used, and studies should be reported according to the STARD (Standards for Reporting Diagnostic Accuracy Studies) guidelines. Clinical or radiographic follow-up may be incorporated into the reference standard definition but should not be used to calculate diagnostic yield from the procedural encounter. Methodologically robust comparative studies, with incorporation of patient-reported outcomes, are needed to adequately assess and validate minimally invasive diagnostic technologies targeting the lung periphery. Conclusions: This American Thoracic Society/American College of Chest Physicians statement aims to provide a research framework that allows greater standardization of device validation efforts through clearly defined diagnostic outcomes and robust study designs. High-quality studies, both industry and publicly funded, can support subsequent health economic analyses and guide implementation decisions in various healthcare settings.

18 July 2024 in Chest
Verified
Journal Article
Closed access
KMKamran Mahmood
Kamran Mahmood
LFLindsy Frazer-Green
Lindsy Frazer-Green
AGAnne V. Gonzalez
Anne V. Gonzalez
SSScott L. Shofer
Scott L. Shofer
AAAngela Christine Argento
Angela Christine Argento
LYLonny Yarmus
Lonny Yarmus

26 November 2010 in Thorax
Verified
Journal Article
Open access
PDF file
AGAnne V Gonzalez
Anne V Gonzalez
SSSamy Suissa
Samy Suissa
PEPierre Ernst
Pierre Ernst
Background Chronic obstructive pulmonary disease (COPD) is a leading cause of morbidity and mortality worldwide. Gender differences in the clinical expression of COPD are increasingly recognised, but outcome differences have not been systematically examined. Gender differences in survival and rate of rehospitalisation were investigated in a large cohort of elderly patients with chronic airflow obstruction hospitalised for COPD. Methods The databases from the Québec provincial health insurance plan were used. The study population included subjects aged >66 years who received ≥3 prescriptions for respiratory medications in any 1-year period between 1 January 1990 and 31 December 2001. The study cohort consisted of patients with a first hospitalisation for COPD, after selection into the study population. Patients were followed until death or 31 December 2003. The Kaplan–Meier method was used to estimate time to death and time to first hospitalisation for obstructive airways disease (COPD or asthma). The Cox proportional hazards model was used to determine the effect of male gender on all-cause mortality and rehospitalisation. Results The cohort consisted of 19 260 women and 23 893 men with a mean age of 77 years. 11 245 (58.4%) women and 16 754 (70.1%) men died after cohort entry. Male sex was associated with a significantly increased risk of death (adjusted HR 1.45, 95% CI 1.42 to 1.49) and with a significantly increased risk of rehospitalisation for obstructive airways disease (adjusted HR 1.12, 95% CI 1.09 to 1.15). Conclusion Mean survival and time to rehospitalisation for obstructive airways disease are significantly better for female patients.

27 September 2024 in Chest
Verified
Journal Article
Closed access
CGChristopher Gilbert
Christopher Gilbert
CDClaire Dust
Claire Dust
AAA. Christine Argento
A. Christine Argento
DFDavid J Feller-Kopman
David J Feller-Kopman
AGAnne V. Gonzalez
Anne V. Gonzalez
LYLonny B. Yarmus
Lonny B. Yarmus

1 June 2010 in Chest
Verified
Journal Article
Closed access
PDF file
AGAnne V. Gonzalez
Anne V. Gonzalez
VBVishnu Bezwada
Vishnu Bezwada
JBJohn F. Beamis
John F. Beamis
AVAndrew G. Villanueva
Andrew G. Villanueva

9 August 2016 in BMJ Open Respiratory Research
Verified
Journal Article
Open access
PDF file
ANAsma Navasakulpong
Asma Navasakulpong
MAManon Auger
Manon Auger
AGAnne V Gonzalez
Anne V Gonzalez
Background Studies have reported a high diagnostic yield of endobronchial ultrasound-guided transbronchial needle aspiration (EBUS-TBNA) for the diagnosis of sarcoidosis. We sought to review the yield of EBUS-TBNA for the diagnosis of sarcoidosis at our institution over time, and examine factors that may influence this yield. Methods Patients who underwent EBUS-TBNA for suspected sarcoidosis between December 2008 and November 2011 were identified. EBUS was performed without rapid on-site evaluation (ROSE) of samples. The final diagnosis was based on the results of all invasive diagnostic procedures and/or clinical follow-up. Logistic regression analysis was used to examine the effect of various factors on yield. Results 43 patients underwent 45 EBUS-TBNA procedures for suspected sarcoidosis. A total of 115 lymph nodes were sampled. The 21 G needle was used in 51% of procedures. The mean number of lymph node stations sampled was 2.6 (SD 0.7) and the mean number of needle passes per procedure was 7.8 (SD 2.0). Non-necrotising granulomatous inflammation was detected in EBUS-TBNA samples from 34/45 (76%) procedures. The overall diagnostic yield increased to 36/45 (80%) following a cytopathology review for this study. Needle gauge, number of lymph node stations sampled and number of needle passes were not associated with diagnostic yield. The yield of EBUS-TBNA increased significantly after the first 15 procedures performed for suspected sarcoidosis; the 2 additional cases diagnosed after the cytopathology review were part of this early experience. Conclusions EBUS-TBNA is a valuable technique for the diagnosis of sarcoidosis when performed without ROSE. The yield of the procedure improved significantly over time, based on operator and cytopathologist experience.